SARS-CoV-2 (COVID-19) Spike 156-157EFdel Antibody (Delta Variant)
1021.39 €
In Stock
quantity
product details
Catalog number: 223 - 9689-01mg
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 0.1 mg
9689-002mg
SARS-CoV-2 (COVID-19) Spike 156-157EFdel Antibody (Delta Variant)
SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent.
474.55 €
BSV-COV-AB-01
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9]
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal)
574.50 €
9793-002mg
SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Antibody (Omicron)
SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, 15 of which are in the receptor binding domain (RBD). Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent.
474.55 €
9793-01mg
SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Antibody (Omicron)
SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, 15 of which are in the receptor binding domain (RBD). Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent.